Photo of Tom Powles taken from bartscancer.london
Apr 8, 2024, 15:41
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X:
“TDXD received FDA accelerated approval in HER2 IHC 3+ treatment-refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing is needed. This seems an ambitious accelerated approval in UC.”
Read further.
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12